Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13cyclopia sequence 7Neoplasms 5Polycystic Ovary Syndrome 4Prostatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Leiomyoma 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vomiting 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Obesity 2Neoplasms, Plasma Cell 2Nausea 2Hematologic Diseases 2Fatigue 2Depression 2Weight Loss 1Warts 1Urinary Bladder Neoplasms 1Testicular Neoplasms 1Sleepiness 1Sezary Syndrome 1Prostatic Intraepithelial Neoplasia 1Primary Myelofibrosis 1Peripheral Nervous System Diseases 1Pediatric Crohn's disease 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1

Interventions

Sugars 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myelitis × Sugars × Clear all
NCT02166346 2018-04-17

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Johns Hopkins University

Phase 2 Completed
24 enrolled 10 charts

Myelitis, Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡